Maja Cikes
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)

Maja Cikes

Zagreb, HR 
Distinguished in Heart Failure with Preserved Ejection Fraction (HFpEF)
Zagreb, HR 
OverviewLocationsClinical Research

Overview

Maja Cikes practices in Zagreb, Croatia. Ms. Cikes is rated as a Distinguished expert by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top areas of expertise are Heart Failure, Heart Failure with Preserved Ejection Fraction (HFpEF), Cardiac Amyloidosis, Heart Transplant, and Lung Transplant.

Her clinical research consists of co-authoring 107 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 20 articles in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Gender
Female

Locations

Zagreb, Croatia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Randomized, Open-label, Parallel Group, Pilot Study to Evaluate the Use of Sacubitril/Valsartan in HeartMate 3 LVAD Recipients
A Multicenter, Randomized, Open-label, Parallel Group, Pilot Study to Evaluate the Use of Sacubitril/Valsartan in HeartMate 3 LVAD Recipients
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2024
Intervention Type: Drug
Study Drugs: Sacubitril-Valsartan, Standard of Care
Study Phase: Phase 4

107 Total Publications

Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy -Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF).
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy -Primary results of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF).
Journal: JACC. Heart failure
Published: July 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Cikes's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile